# Study of Romiplostim for Chemotherapy Induced Thrombocytopenia

> **NCT02052882** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 60 (actual)

## Conditions studied

- Isolated Chemotherapy-induced Thrombocytopenia

## Interventions

- **BIOLOGICAL:** romiplostim

## Key facts

- **NCT ID:** NCT02052882
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-30
- **Primary completion:** 2023-11-13
- **Final completion:** 2023-11-13
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02052882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02052882, "Study of Romiplostim for Chemotherapy Induced Thrombocytopenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02052882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*